Particle.news

White House Withdraws Heidi Overton as FDA Nominee

The decision creates an urgent need for a confirmable FDA nominee before Democrats take control of the Senate in January.

Overview

  • A senior White House official confirmed late Tuesday that the administration has dropped Dr. Heidi Overton’s nomination after concluding she lacked the votes to advance in the Senate.
  • Overton’s bid stalled because she faced opposition from Democrats and key Republicans, including HELP chair Bill Cassidy, over her role in proposed childhood vaccine changes and questions about her managerial experience.
  • Conservative and MAHA movement allies also criticized Overton for perceived industry ties and for not committing to stricter limits on mifepristone access, while anti‑abortion groups pressed for tighter dispensing rules.
  • With the post vacant, the FDA remains under acting Commissioner Kyle Diamantas, and Republicans are quietly discussing Sen. Roger Marshall, who recently lost his reelection, as a possible replacement.
  • The White House now faces a tight window to confirm a new commissioner before Democrats gain the Senate in January, increasing the likelihood of short‑term acting leaders and raising stakes for upcoming FDA decisions such as the mifepristone safety review scheduled for March 2027.